Leuphasyl
What the Research Actually Shows
Human: 0 studies, 1 groups · Animal: 0 · In Vitro: 1
A synthetic enkephalin analog marketed as an Argireline synergist — where the mechanism is speculative, the human evidence is zero, and the entire pathway from jar to wrinkle has never been tested
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Leuphasyl is a synthetic copy of one of your body's natural painkillers — an enkephalin — that someone decided to put in a face cream. The idea is that if you activate opioid receptors on the nerves under your skin, those nerves will send fewer signals to your facial muscles, and your muscles will contract less, and your wrinkles will get shallower. It is a creative hypothesis. It is also completely untested in human beings. No one has published a study showing Leuphasyl reduces wrinkles. No one has shown it even reaches the nerves it is supposed to target. No one has studied whether rubbing an opioid agonist on your face every day for months does anything — good or bad. It is sold almost exclusively as an add-on to Argireline, which makes it impossible to know whether it contributes anything at all. If you use Leuphasyl, you are trusting a marketing department's theoretical mechanism over the complete absence of evidence.
The cosmetic peptide industry has a creativity problem disguised as an innovation problem. When Argireline proved that a peptide could reduce wrinkles (modestly, from a cream), the race was on to find new mechanisms — different angles of attack on the same endpoint: reduced muscle contraction, fewer expression lines, smoother skin. Leuphasyl represents one of the more audacious attempts. Instead of blocking the machinery muscles use to receive signals (the SNARE complex, like Argireline does), Leuphasyl proposes to reduce the signals themselves by activating opioid receptors on the nerve terminals that send them.
It is, on paper, an elegant complementary approach. In practice, it is a hypothesis that has never been tested. No peer-reviewed journal has published a study on Leuphasyl in human subjects. No clinical trial registry contains an entry. The compound's maker, Lipotec (now Lubrizol), markets it almost exclusively as a partner ingredient to Argireline — not as a standalone active — which itself suggests limited confidence in the compound's independent contribution.
The deeper problem is biological plausibility. For Leuphasyl to work as described, it must penetrate the stratum corneum, diffuse to dermal nerve terminals, achieve sufficient local concentration to activate mu-opioid receptors, and produce enough presynaptic inhibition to measurably reduce facial muscle contraction. Each step in that chain is unvalidated. The chain as a whole has never been tested.
For a deeper understanding of how topical peptides navigate the skin barrier — and how microneedling can dramatically improve delivery — see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Leuphasyl at a Glance
Type
Synthetic pentapeptide (5 amino acids); enkephalin analog
Also Known As
Pentapeptide-18, INCI: Pentapeptide-18
Generic Name
Pentapeptide-18
Brand Name
Leuphasyl (Lipotec/Lubrizol)
Molecular Weight
~569 Da (smallest peptide in Cluster G — favorable for penetration)
Peptide Sequence
Tyr-D-Ala-Gly-Phe-Leu (modified leucine-enkephalin with D-alanine substitution for stability)
Endogenous Origin
Based on leucine-enkephalin — one of the body's natural opioid painkillers, produced in the nervous system and immune cells
Primary Molecular Function
Proposed: mu-opioid receptor agonism on dermal sensory nerve terminals, reducing presynaptic acetylcholine release (entirely theoretical — not validated in skin)
Active Fragment
Full pentapeptide is the proposed active form; D-Ala substitution provides protease resistance absent in natural enkephalins
Delivery Methods
Topical (in multi-peptide blend formulations, rarely standalone) · Not used as injectable in cosmetic context
Clinical Programs
None. Zero registered clinical trials. Zero published human efficacy studies. All data is proprietary Lipotec marketing material.
Route
Topical application in cream or serum, almost exclusively in combination with Argireline
FDA Status
Category A — accepted cosmetic ingredient (INCI registered); not a drug; no therapeutic claims permitted
WADA Status
Not prohibited (cosmetic, topical, negligible systemic absorption; though technically an opioid receptor agonist)
Community Interest
Marketed as an Argireline synergist — "two mechanisms, one endpoint" — but without standalone evidence of efficacy
Opioid Receptor Concern
Leuphasyl is an opioid agonist. Chronic topical opioid receptor stimulation has never been studied for tolerance, withdrawal, or immunological effects.
Evidence Tier
4 Preclinical Only
Verdict
Thin Ice
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Leuphasyl? — Origins and Discovery
Pronunciation: LOO-fah-sil
Your body makes its own painkillers. They are called enkephalins — five-amino-acid peptides that activate the same opioid receptors that morphine targets. When you stub your toe and the initial agony fades to a dull ache, enkephalins are part of the reason. When a runner hits the wall and then pushes through it, enkephalins help dull the signal. These tiny peptides are ancient, powerful, and extraordinarily well-studied — in the context of pain. Someone at Lipotec looked at enkephalins and asked a different question: what if an opioid agonist could reduce wrinkles?
The logic goes like this. Facial expression lines form because muscles contract repeatedly. Muscles contract because nerves release a chemical called acetylcholine. Nerves have opioid receptors. When you activate an opioid receptor on a nerve terminal, that nerve releases less neurotransmitter. So if you put an enkephalin analog on your skin and it reaches the nerves underneath, those nerves should release less acetylcholine, your muscles should contract less forcefully, and your wrinkles should get shallower. It is the same endpoint as Argireline — reduced muscle contraction — but achieved through a completely different mechanism.
Lipotec synthesized Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu), substituting a D-alanine in the second position to make the peptide resistant to the enzymes that would normally destroy a natural enkephalin in minutes. They named it Leuphasyl and marketed it as a companion to their flagship Argireline — two peptides attacking the same problem from opposite sides of the synapse. The marketing was imaginative. The science stopped at the marketing.
PLAIN ENGLISH
Leuphasyl is a lab-made copy of one of your body's natural painkillers. The idea is that if it reaches the nerves under your skin, those nerves will tell your facial muscles to relax a little, and your wrinkles will soften. It is an interesting idea that nobody has tested on a real face.
Mechanism of Action
Opioid Receptor Signaling: A CNS Mechanism Applied to Skin
Opioid receptors (mu, delta, and kappa subtypes) are G-protein-coupled receptors found throughout the nervous system and immune system. When activated by endogenous ligands (endorphins, enkephalins, dynorphins) or exogenous agonists (morphine, fentanyl), they produce analgesia, euphoria, respiratory depression, and a cascade of downstream effects including reduced neurotransmitter release from presynaptic terminals.
Leuphasyl's proposed mechanism borrows from this well-established pharmacology but applies it in a context where it has never been validated: dermal sensory nerve terminals. The proposed pathway:
1. Topical application delivers Leuphasyl through the stratum corneum 2. Dermal diffusion brings the peptide to sensory nerve endings in the papillary dermis 3. Mu-opioid receptor activation on presynaptic terminals reduces calcium influx 4. Reduced vesicle exocytosis means less acetylcholine release at the neuromuscular junction 5. Weaker muscle contraction produces shallower expression lines
Why Each Step Is Unvalidated
Step 1 — Penetration: Leuphasyl (569 Da) is smaller than Argireline (889 Da), which is favorable for transepidermal penetration. However, no published study has measured Leuphasyl penetration through human skin. The assumption is extrapolated from general peptide penetration data.
Step 2 — Target access: Sensory nerve terminals reside in the papillary dermis, approximately 0.1–0.3 mm below the skin surface. Motor nerve terminals (which actually control facial muscles) are much deeper — at the neuromuscular junction, typically 1–2 mm deep. It is unclear which nerve population Leuphasyl is supposed to target, and whether either is accessible from topical application.
Step 3 — Receptor activation: Opioid receptors are present on dermal sensory neurons, but their density, subtype distribution, and functional coupling in skin are poorly characterized. Whether topically delivered enkephalin analogs achieve sufficient local concentration to activate these receptors is unknown.
Steps 4–5 — Functional cascade: Even if receptor activation occurs, the magnitude of acetylcholine reduction required to produce a measurable cosmetic effect is unknown. The entire downstream pathway from "opioid receptor activation on a dermal nerve" to "measurable wrinkle reduction" has never been demonstrated.
How This Differs from Argireline
Argireline and Leuphasyl both aim to reduce acetylcholine release, but from different sides:
Argireline (postsynaptic approach): Competes with SNAP-25 at the nerve terminal, directly interfering with the vesicle fusion machinery that releases acetylcholine. The target — the SNARE complex — is well-characterized and directly relevant.
Leuphasyl (presynaptic approach): Activates opioid receptors upstream, which should reduce calcium influx and vesicle docking. The target — dermal nerve opioid receptors — is poorly characterized and cosmetically unvalidated.
The marketing narrative positions these as complementary mechanisms that "converge" on the same endpoint. Whether convergence occurs in practice has never been tested.
PLAIN ENGLISH
Argireline jams the machine that muscles use to fire. Leuphasyl tries to reduce the fuel supply to that machine by activating painkiller receptors on the nerves. The jamming approach has human evidence. The fuel-reduction approach is a guess that no one has checked.
Key Research Areas and Studies
The Evidence Base: Proprietary and Theoretical
All data on Leuphasyl comes from Lipotec (now Lubrizol). No independent laboratory has published any study on Pentapeptide-18 in any peer-reviewed journal.
Study 1: Enkephalin Mechanism Paper (Lipotec, ~2006)
Design: Literature review and theoretical framework Key finding: Describes enkephalin receptor biology and proposes application to dermal nerve terminals for cosmetic use. Interpretation: This is a hypothesis paper, not experimental evidence. It describes well-known opioid pharmacology and extrapolates to a cosmetic context. No original data.
Study 2: Cosmetic Marketing Panel (Lipotec, ~2008)
Design: Unpublished cosmetic trial; details sparse Key finding: A multi-peptide blend containing Argireline + Leuphasyl reportedly showed wrinkle reduction in volunteers (N unknown, duration unknown). Interpretation: Not a clinical trial. No randomization, no blinding, no placebo control, no published statistical analysis. Critically, because Argireline and Leuphasyl were tested together, it is impossible to determine whether Leuphasyl contributed any independent effect. The results may be entirely attributable to Argireline.
The Search That Finds Nothing
PubMed returns zero results for "Leuphasyl" and zero results specific to Pentapeptide-18 in a cosmetic context. ClinicalTrials.gov returns zero registered studies. Google Scholar returns marketing materials only. After approximately eighteen years on the market, Leuphasyl has generated no independently verifiable evidence of any kind.
PLAIN ENGLISH
The sum total of evidence for Leuphasyl is: a company described a theory about how it might work, and then ran an unpublished test where it was mixed with another peptide that already has evidence. That is everything. There is nothing else.
The Argireline Synergy Question
The Central Problem with "Synergy" Claims
Leuphasyl is almost never sold alone. It appears in "Argireline + Leuphasyl" combination products marketed as dual-mechanism formulations. The synergy claim rests on complementary pharmacology: postsynaptic inhibition (Argireline) plus presynaptic inhibition (Leuphasyl). Theoretically, attacking acetylcholine release from both sides should produce a greater effect than either alone.
Why No One Has Tested This
A definitive synergy study would require four arms: (1) Argireline alone, (2) Leuphasyl alone, (3) Argireline + Leuphasyl, (4) placebo. This study has never been conducted. Without it, the synergy claim is mathematical speculation, not evidence.
The More Likely Explanation
Products containing "Argireline + Leuphasyl" that show wrinkle reduction are most parsimoniously explained by Argireline's established efficacy. Leuphasyl's contribution is unknown and may be zero. Consumers paying a premium for the combination product may be paying for one active ingredient and one theoretical additive with no independent validation.
PLAIN ENGLISH
"Synergy" is a science word that sounds precise but here means "we put two things together and didn't test whether both are doing something." It is possible Leuphasyl adds to Argireline's effect. It is equally possible you are paying extra for an ingredient that does nothing.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Leuphasyl activates opioid receptors to reduce wrinkles"” | Structural analog of enkephalin; should bind opioid receptors. Whether it penetrates skin, reaches nerve terminals, activates receptors at cosmetic concentrations, and produces wrinkle reduction is entirely untested. | Theoretical |
| “"Works synergistically with Argireline for enhanced results"” | Never tested in a study comparing Argireline alone vs. Argireline + Leuphasyl. The combination effect may be entirely attributable to Argireline. | Unsupported |
| “"Reduces expression lines through presynaptic inhibition"” | Proposed mechanism. No human data. No in vivo validation. The pathway from topical application to presynaptic opioid signaling in dermal nerve terminals is entirely theoretical. | Theoretical |
| “"Two mechanisms are better than one"” | Logical premise. Zero empirical validation. Without a controlled comparison, the additive value of a second mechanism is speculative. | Theoretical |
| “"Safe for daily topical use"” | No published human safety data. No tolerance studies. Chronic topical opioid receptor agonism has never been studied. Safety is assumed, not demonstrated. | Preclinical Only |
| “"More effective than Argireline alone"” | Never tested. No head-to-head data. No standalone Leuphasyl efficacy data. | Unsupported |
| “"An advanced anti-aging peptide"” | Marketing language. Leuphasyl has zero human evidence and is not validated as an anti-aging agent. | Unsupported |
| “"Based on the body's natural painkillers"” | Structurally true — Leuphasyl is based on leucine-enkephalin. But "based on" a natural molecule does not validate cosmetic efficacy. Cobra venom is "based on" a natural molecule too. | Mixed Evidence |
| “"Reduces acetylcholine release from facial nerves"” | Theoretical. Opioid receptor activation does reduce neurotransmitter release in the nervous system. Whether this occurs in dermal nerve terminals from topical application is undemonstrated. | Theoretical |
| “"Non-toxic and well-tolerated"” | No human toxicity or tolerability data exists. Safety is inferred from peptide chemistry and similarity to Argireline. | Preclinical Only |
| “"Better penetration due to smaller molecular size"” | Leuphasyl (569 Da) is smaller than Argireline (889 Da), which is theoretically favorable for skin penetration. No Leuphasyl-specific penetration data has been published. | Theoretical |
| “"Clinically proven in combination with Argireline"” | No published clinical trial exists for any Leuphasyl-containing formulation. Proprietary cosmetic panel data (unpublished, no details) does not constitute clinical proof. | Unsupported |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
The Landscape Does Not Exist
Leuphasyl has no human evidence landscape to evaluate. This section exists because every compound article requires it — and in this case, the honest content is a description of absence.
PubMed: Zero results for "Leuphasyl." Zero results for "Pentapeptide-18" in any cosmetic or dermatological context. ClinicalTrials.gov: Zero registered studies. Google Scholar: Marketing materials and cosmetic trade publications only. Manufacturer data: One unpublished cosmetic panel testing a blend with Argireline. No standalone Leuphasyl data. No study design details.
What Would Need to Happen
For Leuphasyl to move beyond Tier 4, at minimum: - A published study demonstrating that Leuphasyl (standalone, not in a blend) produces measurable wrinkle reduction in human subjects - Independent validation from a laboratory not affiliated with Lipotec/Lubrizol - Evidence that the proposed mechanism (dermal opioid receptor activation) actually occurs in human skin
None of these studies appears to be planned, registered, or in progress. After eighteen years of commercial availability, the evidence landscape for Leuphasyl remains a blank page.
PLAIN ENGLISH
There are no human studies on Leuphasyl. Not small ones, not bad ones, not old ones — none. The only "test" involved mixing it with Argireline and not publishing the results. If you use this compound, you are the only evidence that will ever exist about your experience with it.
Safety, Risks, and Limitations
The Opioid Question
Leuphasyl is, chemically, an opioid receptor agonist. In the context of skin cream applied to crow's feet, this sounds absurd — and the systemic exposure is almost certainly negligible. However, the safety implications of chronic topical opioid receptor stimulation have never been studied:
Tolerance: Opioid receptors are known to downregulate with chronic agonist exposure. Whether dermal nerve opioid receptors develop tolerance to chronic topical Leuphasyl exposure is unknown. If they do, any cosmetic effect would diminish over time.
Immune modulation: Opioid receptors on dermal immune cells (Langerhans cells, mast cells, keratinocytes) modulate local immune function. Chronic opioid agonism might affect wound healing, inflammation, or susceptibility to skin infections. Not studied.
Local effects: Opioid agonism on sensory nerves produces analgesia. Whether daily Leuphasyl application produces measurable local numbness, altered sensation, or itch modulation is unknown.
General Safety Profile
Dermal irritation: Not formally tested. Assumed minimal based on peptide chemistry. Allergic reactions: Not documented. Limited market penetration means rare events would go undetected. Systemic absorption: Expected to be negligible for a topical pentapeptide. Not measured. Drug interactions: None documented. Theoretical concern: concurrent use of topical analgesics (lidocaine patches, capsaicin cream) might produce unexpected interactions at dermal nerve terminals, though this is highly speculative.
The Honest Safety Statement
Leuphasyl is almost certainly harmless in the way that most topical peptides are harmless — negligible systemic absorption, no known toxic effects, no reports of adverse events. But "almost certainly harmless" based on a complete absence of safety data is a different statement from "demonstrated safe." For a compound with an unconventional mechanism (topical opioid agonism), the absence of safety data is more notable than it would be for a conventional cosmetic peptide.
PLAIN ENGLISH
Leuphasyl is probably safe to put on your face. But nobody has actually checked — and calling it a "topical opioid agonist" raises questions that "topical moisturizing peptide" does not. The questions are probably academic. They are also unanswered.
Legal and Regulatory Status
FDA Classification
Leuphasyl is classified as a cosmetic ingredient under the INCI system (Pentapeptide-18). It is not regulated as a drug despite being an opioid receptor agonist — the distinction rests on intended use (cosmetic, not therapeutic) and route (topical with negligible systemic absorption). Products containing Leuphasyl may claim to "reduce the appearance of" wrinkles but may not make drug claims.
International Status
Accepted for cosmetic use in the European Union, China, Japan, Australia, and most global markets. No prescription required.
WADA Status
Not on the 2025 or 2026 World Anti-Doping Agency Prohibited Lists. Cosmetic topical peptides with negligible systemic absorption are outside WADA's scope. Note: if systemic absorption were demonstrated, WADA classification might differ, as opioids are prohibited in competition.
Research Protocols and Formulation Considerations
Typical Formulation
Leuphasyl is supplied as a concentrated solution and is almost exclusively formulated in multi-peptide blends with Argireline. Standalone Leuphasyl serums are rare. Typical concentrations in finished products are 3–5% of the stock solution (yielding approximately 0.15–0.25% active peptide).
Stability
The D-alanine substitution provides resistance to L-amino acid peptidases, giving Leuphasyl significantly longer half-life in biological fluids compared to natural enkephalins (which are degraded within minutes). In formulation, stability is maintained at pH 4.0–6.0 with standard cosmetic preservatives.
Delivery Enhancement
At 569 Da, Leuphasyl is the smallest peptide in Cluster G — theoretically favorable for transepidermal penetration. Enhanced delivery methods (microneedling, liposomal encapsulation) could improve delivery, but no Leuphasyl-specific delivery data exists.
For context on topical peptide delivery and microneedling protocols, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).
Dosing in Published Research
No Research-Based Dosing Data
Because no human clinical trial has been conducted, there are no evidence-based dosing recommendations for Leuphasyl.
In Vitro Context
| Context | Concentration | Notes |
|---|---|---|
| Opioid receptor activation (general enkephalin pharmacology) | IC50 typically 1–100 nM | General opioid pharmacology; not specific to Leuphasyl |
| Cosmetic formulation | 0.15–0.25% (w/v) active peptide | Stock solution diluted in finished product |
The Concentration Gap
Opioid receptor activation typically requires nanomolar concentrations. Whether topical application of a cosmetic formulation delivers Leuphasyl to dermal nerve terminals at nanomolar or higher concentrations has never been measured.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Leuphasyl has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Community Usage Patterns
Leuphasyl has minimal standalone community presence. It appears primarily in pre-formulated multi-peptide products.
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical (in multi-peptide blend) | Twice daily as part of Argireline combination product | No human evidence for Leuphasyl contribution | 3–5% solution in product | None documented; contribution to efficacy unknown |
| Topical (standalone serum) | Rare; some DIY formulations | No evidence | 3–5% solution | No known risks; no known benefits either |
| Topical + microneedling | Theoretical | No data | Standard concentration | Microneedling risks apply; peptide delivery uncharacterized |
Community Perception
Leuphasyl has low visibility in skincare communities. When discussed, it is typically mentioned alongside Argireline as part of "peptide stacking" protocols. Community consensus generally acknowledges the lack of evidence and treats Leuphasyl as a speculative addition rather than a proven active.
PLAIN ENGLISH
Almost nobody uses Leuphasyl by itself. It shows up in products that combine it with Argireline, and most people in skincare communities who know about it acknowledge it is unproven.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Leuphasyl combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Leuphasyl with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Leuphasyl Compares
Leuphasyl belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Leuphasyl is a synthetic enkephalin analog marketed as a cosmetic anti-wrinkle peptide. Its proposed mechanism — presynaptic opioid receptor-mediated inhibition of acetylcholine release — is borrowed from well-established neuropharmacology but applied to a context (dermal nerve terminals accessed via topical cream) where it has never been validated.
The compound has zero published human efficacy data. No clinical trial has been registered. No peer-reviewed study exists. The only claimed human data comes from an unpublished cosmetic panel testing Leuphasyl in combination with Argireline — making it impossible to isolate Leuphasyl's independent contribution.
The mechanism itself contains multiple unvalidated assumptions: that Leuphasyl penetrates the stratum corneum at sufficient concentration, that it reaches dermal nerve terminals, that it activates opioid receptors at the concentrations achievable from topical delivery, and that this activation produces enough presynaptic inhibition to measurably reduce wrinkle formation. None of these steps has been demonstrated.
Leuphasyl is marketed primarily as an Argireline synergist — a companion ingredient that adds theoretical value to an established active. This positioning suggests even the manufacturer views it as supplementary rather than independently effective. Consumers should not pay a premium for Leuphasyl-containing products over Argireline-only products, as there is no evidence the combination provides benefit beyond what Argireline delivers alone.
PLAIN ENGLISH
Leuphasyl is a creative idea that nobody has tested. It borrows a mechanism from painkiller science and applies it to wrinkle cream — without ever checking whether the mechanism works through skin. If you want a peptide that has actually been shown to reduce wrinkles in real people, choose Argireline or Matrixyl. If you want to try something experimental with no evidence, Leuphasyl is available — but know exactly what you are buying.
Verdict Recapitulation
Leuphasyl earns the Thin Ice verdict not because it is dangerous — it is almost certainly harmless — but because the gap between its marketing narrative and its evidence base is among the widest in Cluster G. A compound with zero human data, an unvalidated mechanism, and no standalone positioning is the definition of thin ice. The ice may hold. But you are walking on it blind.
For readers considering Leuphasyl, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Leuphasyl
Further Reading and Resources
If you want to go deeper on Leuphasyl, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Leuphasyl — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Lipotec S.A. (2006). Mechanism paper: Enkephalin receptor signaling and theoretical application to dermal nerve terminals. (Proprietary; not published; no original experimental data.)
- Lipotec S.A. (2008). Cosmetic panel: Argireline + Leuphasyl blend in human volunteers. (Proprietary; not published; no study design details available.)
- Hughes, J. et al. (1975). "Identification of two related pentapeptides from the brain with potent opiate agonist activity." Nature, 258(5536), 577–580. PMID 1207728
- Gorouhi, F. and Maibach, H.I. (2009). "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 31(5), 327–345. PMID 19570099
- Schagen, S. (2017). "Topical Peptide Treatments with Effective Anti-Aging Results." Cosmetics, 4(2), 16
- Blanes-Mira, C. et al. (2002). "A synthetic hexapeptide (Argireline) with antiwrinkle activity." International Journal of Cosmetic Science, 24(5), 303–310. PMID 18498523
- Stein, C. et al. (1995). "Peripheral opioid receptors." Annals of Medicine, 27(2), 219–221. PMID 7632416
- Bigliardi, P.L. et al. (2009). "Opioids and the skin — where do we stand?" Experimental Dermatology, 18(5), 424–430. PMID 19382312
DISCLAIMER
Leuphasyl is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.